Table 2.
Association of ASF1B expression and clinicopathological parameters in patients with gliomas.
| Characteristic | ASF1B expression in the TCGA database | ASF1B expression in the CGGA database | ||||
|---|---|---|---|---|---|---|
| Low | High | P-value | Low | High | P-value | |
| n = 348 | n = 348 | n = 346 | n = 347 | |||
| WHO grade, n (%) | <0.001 | <0.001 | ||||
| G2 | 188 (29.6%) | 36 (5.7%) | 149 (21.5%) | 39 (5.6%) | ||
| G3 | 117 (18.4%) | 126 (19.8%) | 129 (18.6%) | 126 (18.2%) | ||
| G4 | 4 (0.6%) | 164 (25.8%) | 68 (9.8%) | 181 (26.2%) | ||
| IDH status, n (%) | <0.001 | <0.001 | ||||
| WT | 35 (5.1%) | 211 (30.8%) | 206 (32.1%) | 150 (23.4%) | ||
| Mut | 310 (45.2%) | 130 (19%) | 102 (15.9%) | 184 (28.7%) | ||
| 1p/19q codeletion, n (%) | <0.001 | <0.001 | ||||
| codel | 131 (19%) | 40 (5.8%) | 86 (13.8%) | 59 (9.5%) | ||
| non-codel | 216 (31.3%) | 302 (43.8%) | 196 (31.5%) | 282 (45.3%) | ||
| Gender, n (%) | 0.399 | 0.374 | ||||
| Female | 155 (22.3%) | 143 (20.5%) | 141 (20.3%) | 154 (22.2%) | ||
| Male | 193 (27.7%) | 205 (29.5%) | 205 (29.6%) | 193 (27.8%) | ||
| Age, n (%) | <0.001 | 0.012 | ||||
| ≤60 | 315 (45.3%) | 238 (34.2%) | 321 (46.4%) | 300 (43.4%) | ||
| >60 | 33 (4.7%) | 110 (15.8%) | 25 (3.6%) | 46 (6.6%) | ||
| Age, median (IQR) | 39 (32, 49) | 54 (40, 63) | <0.001 | 42 (34, 50) | 44 (34, 54) | 0.056 |